Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 8
Submit an article Journal homepage
17
Views
10
CrossRef citations to date
0
Altmetric
Research

Section Review Anti-infectives: The future role of quinolones

Daniel TW Chu Abbott Laboratories, D-47N, 100 Abbott Park Road, Abbott Park, IL, 60064-3500, USA
Pages 711-737 | Published online: 29 Feb 2008

References to Primary Literature

  • LESHER GY, FROELICH EL GRUETT MD, BAILEY JH, BRUN-DAGE RP: 1,8- Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. (1962) 5:1063–1065.
  • SMITH JT: Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical J. (1984) 233:299–305.
  • K KOGA H, ITOH A, MURAYAMA 5, SUZUE S, IRLKURA T: Structure-activity relationships of antibacterial 6, 7- and 7, 8-disubstituted 1-alkyl-1,4- dihydro-4 oxoquinoline-3-carboxylic adds. J Med. Chem. (1980) 23:1358–1363.
  • WISE R, ANDREWS JM, EDWARDS LJ: In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrobial Agents and Chemotherapy (1983) 23:559–564.
  • SATO K, MATSUURA Y, INOUE M, UNE T, OSADA Y, of DL-8280, anew oxazine derivative. Anttmicrob. Agents. Chemother. (1982) 22:548–553.
  • MATSUMOTO J, MIYAMOTO T, MINAMIDA A, NISHIMURA Y, EGAWA H, NISHIMURA H: Pyridonecarlboxylic adds as antibacterial agents. 2. Synthesis and structure-activ-ity relationships of 1, 6, 7, -trisubstituted 1,4,- dihydro-4-oxo-1,8-naphthyricline-3-carlboxylic acids, including enoxacin, a new antibacterial agent. J. Med. Chem. (1984) 27:292–301.
  • CHU DTW, FERNANDES PB, CLAIBORNE AK, GRACEY HE,PERNET AG: Synthesis and structure-activity relation-ships of new arylfluoronaphthyridine antibacterial agents. J. Med. Chem. (1986) 29: 363–2369.
  • SOEJIMA R, SHIMADA K: Tosufloxacin tosylate. DrugsFuture (1989) 14:536–538.
  • MIYAMOTO T, MATSUMOTO J, CHIBA K, EGAWA H,SHIBAMORI K, MINAMIDA A, NISHIMURA Y, OKADA H, KATASOKA M, FujrrA M, HIROSE T, NAKANO J: Pyridone-carboxylic adds as antibacterial agents. 14. Synthesis and structure-activity relationships of 5-substituted 6, 8- difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med, Chem. (1990) 33:1645–1656.
  • BARRY AL, FUCHS PC: In vitro activities of sparfloxacin, tosufloxadn, ciprofloxacin, and fleroxadn. Antimicrob. Agents Chemother. (1991) 35:955–960.
  • FERNANDES PB, SHIPKOWITZ N, BOWER RR, JARVIS KP, WIESZ J, CHU DT: In Vitro and in vivo Potency of Five New Fluoroquinolones Against Anaerobic Bacteria. J. Antimicrob. Chernother. (1986) 18:693–701.
  • HARDY DJ, SWANSON RN, HENSEY DM, RAMER NR, BOWER RR, HANSON CW, CHU DTW, FERNANDES PB: Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroqui-nolones. Antimicrob. Agents Chemother. (1987) 31:1768–1774.
  • HOOPER DC: New quinolone antibacterial agents. In: Micro bio. (Leive L, Eds.) pp. 217–230 (1986). Amer. Soc. of Microbiol., Washington, D.C.
  • KENNY GE, HOOTON TM, ROBERTS MC, CARTWRIGHT FD, HOYT J: Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilu-tion method. Antimicrob. Agents Chemother. (1989) 33:103–107.
  • KRAUSSE R, ULLMANN U: Comparative in vitro activity of fteroxacin (RD 23-6240) against Ureaplasma urea-41ticum andMycoplasnsa bominis. Eur.J. Clin. Microbiol. & Inf. Dis. (1988) 7:67–69.
  • NICOLLE L, URIAS B, BRUNKA J, KENNEDY J, HARDING G: Comparative in vitro activity of lomefloxadn and other quinolones for gram negative organisms isolated from complicated urinary infection. Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., Los Angeles. (1988) Abst. 687
  • TJIAM KH, WAGENVOORT JH, VAN ICLINGEREN B, PIOT P, STOLZ E, MICHEL MF: In vitro activity of the two new 4-quinolones A56619 and A56620 against Mycopiasma bomittis, Ureaplasma urealyticum and Gardnerella vaginalis Eur.J. Clin. Microbiol. (1986) 5:498–501.
  • WOLFSON JS, HOOPER DC: Fluoroquinolone antimicro-bial agents. Clin. Microbiol. Rev. (1989) 2:378–424.
  • ANDRIOLE VT: The Quinolones. (1988) Academic Press, London.
  • LEIGH DA, WALSH B, HARRIS K, HANCOCK P, TRAVERS G: Pharmcokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J. Antimicrob. Chemother. (1988) 22 (Supp. C):115–125.
  • MOELLERING RC, NEU HC: Introduction: Ofloxacin. Am. J Med. (1989) 87:1s.
  • MOUTON Y, LEROY 0: Review: Ofloxadn. Int.J. Antimi-crob. Agents. (1991) 1:57–74.
  • Shah PM: Review: Ciprofloxacin. Int.J. Antimicrob. Agents. (1991) 1:75–96.
  • SIPORIN C: The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and tcoddties. In Annu. Rev. Microbial. (ORNSTON LN, BALOWS A, GREENBERG EP, Eds.) (1989) pp. 601–625. Annual Reviews Inc., Palo Alto, California.
  • SPELLER D, WISE R: Preface. J. Antimicrob. Chemother. (1988) 21:1.
  • GELLERT M, MIZUUCHI K, O'DEA MIT, ITOH T, TOMIZAWAJ-I: DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci., USA. (1976) 73:3872–3876.
  • GELLERT M, MIZUUCHI K, O'DEA MH, ITOH T, TOMIZAWAJ.-I: Nalidixk acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl, Acad. Sci., USA. (1977) 74:4772–4776.
  • SUGINO A, PEEBLES CL, COZZARELLI NR, KREUZER KN: Mechanism of action of nalidixic acid: Purification of E. coli nalel gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci., USA. (1977) 74:4767–4771.
  • COZZARELLI NR: DNA gyrase and the supercoiling of DNA. Science (1980) 207:953–960.
  • GELLERT M: DNA topoisomerases. Ann. Rev. Biochem. (1981) 50:879–910.
  • REECE RJ, MAXWELL A: DNA gyrase: structure and func-tion. Critical Reviews in Biochemistry and Molecular Biology (1991) 26:335–375.
  • SUTCLIFFE JA, GOOTZ TD, BARRETT JF: Biochemicalcharacteristics and physiological significance of major DNA topoisomerases. Antimicrob. Agents Chemother. (1989) 33:2027–2033.
  • WANG JC: DNA topoisomerases. Sci. Am. (1982) 247:94–109.
  • MORRISON A, COZZARELLI NR: Contacts between DNAgyrase and its binding site on DNA: Features of symme-try and asymmetry revealed by protection from nucle-ases. Proc. Natl, Acad. Sci., USA (1981) 78:1416–1420.
  • THORNSBERRY C, BROWN SD, BOUCHILLON SK, MARLERJ, RICH T, YEE YC: United States surveillance of clinical bacterial isolates to ciprofloxacin. (1993) Institute for Microbiology Research, Franklin, Tennessee.
  • SREEDHARAN S, ORAM M, JENSEN B, PETERSON LR, FISHER LM: DNA gyrase gyrA mutations in ciproflox-adn-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Es-cbericbia colt J. Bact. (1990) 172:7260–7262.
  • KAATZ GW, SE0 SM, RUBLE CA: Efflux-mediated fluoro-quinolone resistance in Staphylococcus aureus. Antimi-crob. Agents Chemother. (1993) 37:1086–1094.
  • YOSHIDA H, BOGAKI M, NAKAMURA M, NAKAMURA S:Quinolone resistance- determining region in the DNA gyrasegyrA gene of Escbericbia coll. Antimicrob. Agents Chemother. (1990) 34:1271–1272.
  • FERNANDES PB: Mode of action, and in vitro and in vivoactivities of the fluoroquinolones. J. Clin. Pharmacol. (1988) 28:156–168.
  • HOIBY N: Clinical uses of nalidixic add analogues: The fluoroquinolones. Eur.J. Clin.Microbiol. (1986) 5:138–140.
  • HOOPER DC, WOLFSON JS: The fluoroquinolones: phar-macology, clinical uses, and toxicities in humans. An-timicrob. Agents Chemother. (1985) 28:716–721.
  • JANKNEGT R: Fluorinated quinolones. A review of their mode of action, antimicrobila activity, pharmacolden-tics and clinical efficacy. Pharm. Weekbl. (Sal (1986) 8:1–21.
  • MAPLE P, BRUMFITT W, HAMILTON-MILLER JM: A reviewof the antimicrobial activity of the fluoroquinolones j. Cbemother. (1990) 2:280–294.
  • NEU HC: Clinical Use of the quinolones. The Lancet (1987)1319–1322.
  • NEU HC: Clinical utility of dna gyrase inhibitors. Phar-mac, Then (1989) 41:207–221.
  • PATON JF1, REEVES DS: 1Fluoroquinolone antibiotics: Microbiology, pharmacokinetics and clinical use. Drugs (1988) 36:193–228.
  • WALKER RC, WRIGHT AJ: The fluoroquinolones. Mayo Clin. Proc. (1991) 66:1249–1259.
  • WOLFSON JS, HOOPER DC: The fluoroquinolones: struc-tures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. (1985) 28:581–586.
  • GOOTZ TO, MCGUIRK PR: New quinolones in develop-ment. Expert Opin. Invest. Drug. (1994) 3(2):93–114.
  • CHU DTW, LINUS LL: Quinolones: Synthetic antibacterial agents. 50 years of Microbials. Society for General Microbi-ology. (DASBY GK, HUNTR PA, RUSSELL AD Eds.) (1995) 53:111–137.
  • CHU DT, FERNANDES PB: Structure-activity relation-ships of the fluoroquinolones. Antimicrob. agents Chemother. (1989) 33:131–135.
  • CORNETT JB, WENTLAND MP: Quinolone antibacterialagents. Annu. Rpt. Med. Chem. (1986)139–148. Academic Press, Orlando.
  • DOMAGALA JM: Structure-activity and structure-side-ef-fect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. (1994) 33:685–706.
  • MITSCHER LA, ZAVOD RM, SHARMA PN, CHU DTW, SHENLL, PERNET AG: Recent advances on quinolone anthni-crobial agents. In Horizons on Antibiotic Research (1988) (DAVIS B D, ICHIKAWA T, MAEDA K, MITSCHER LA eds.) pp. 166–193. Japan Antibiotics Research Association,
  • MITSCHER LA, DEVASTHALE PV, ZAVOD RM: Structure-activity relationships of fluoro-4-quinolones. In The 4-Quinolones: Anti-bacterial Agents In Vitro (1990) (CRUM-PLIN GC Ed.) pp. 115–146. Springer-Verlag, New York.
  • SCHENTAG J, DOMAGALA J: Structure-activity relation-ships with the quinolone antibiotics. Res. Clin. Forums (1985) 7:9–13.
  • RADL S.: Structure-activity relationships in DNA gyrase inhibitors. Pbarmac Tber. (1990) 48:1–17.
  • CHU DTW, FERNANDES PB: Recent Development in the Field of Quinolone Antibacterial Agents. Adv. in Drug Res. (1991) 21:39–144 .
  • CRUMPLIN GC: The 4-quinolones: Antibacterial agents in vitro. (1990) Springer-Verlag, London. (CRUMPLIN G C, Ed.)
  • FERNANDES PB: International Telesymposium on Qui- nolones . (1989) Prous, J. R., Barcelona, Spain. (FERNANDES PB, ed.)
  • ROSEN T: The fluoroquinolone antibacterial agents. In Progress in Medicinal Chemistry (1990) (ELLIS G P, WEST G B, eds.) pp. 235–295. Elsevier Science Publishers, Amsterdam.
  • SIPORIN C, HEIFETZ CL, DOMAGALA JM: The new generation of quinolones . (1990) M. Dekker, New York.
  • BARRETT MS, JONES RN, ERWIN ME, JOHNSON DM, BRIGGS BM: Antimicrobial activity evaluations of two new quinolones, PD 127391 (CI-960 and AM-1091) and P1)131628. Diagn. Micro biol. Infect. Dis. (1991) 14:389–401.
  • GOOTZ TD, BRIGHTY RE, ANDERSON ME, HASKELL SL,SUTCLEFFE JA, CASTALDI MI, MILLFR SA: In vitro activity and synthesis of CP-99,219, a novel 7-(3- azabicy-clo[3.1.0]hexyl)naphthyridone. 32nd Interscience Conf Antimicrobial Agents Chemother., Anaheim (1992) Abstr:751.
  • SATO K, HOSHINO K, TANAKA M, HAYAKAWA I, OSADAY: Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemotber. (1992) 36:1491–1498.
  • HIRAI K, ISHIZAKI T, KOIKE T, IWASE K, HOSAKA M,NIWATA Y, ASAHINA Y, SUZUE S, MASUZAWA K: AM-1091: Synthesis and antibacterial activity of the novel chloro-fluoro-quinolone derivative and its analogs. 26th Inter-science Conf Antimicrobial Agents Chemother,, New Orleans (1986) Abstr:436.
  • WISE R, ASSY JP, ANDREWS JM: In vitro activity of PD127,391, an enhanced-spectrum quinolone. Antimicrob. Agents Chemother. (1988) 32:1251–1256
  • NORRBY SR, JONSSON M: Comparative in vitro activityof PD 127,391, a new fluorinated 4-quinolone deriva-tive. Antimicrob. Agents Chemother. (1988) 32:1278–1281.
  • BARRY AL, FUCHS PC: Antistaphylococcal activity of thefluoroquinolones CI-960, P1)131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur. J Clin. Microbiol. Dis. (1991) 10:168–171.
  • FORSTALL GJ, KNAPP CC, WASHINGTON JA: Activity ofnew quinolones against ciprofloxacin-resistant staphy-lococci. Antimicrob. Agents Chemother. (1991) 35:1679–1681.
  • FUCHS PC, BARRY AL, PFALLER MA, ALLEN SD, GERLACHEH: Multicenter evaluation of the in vitro and in vivo activities of three new quinolones, sparfloxacin, CI-960 and PD 131628, compared with the activity of ciproflox-acin against 5,252 clinical bacterial isolates. Antimicrob. Agents Chemother. (1991) 35:764–766.
  • MIRANDA AG, WANGER AR, SINGH KU, MURRY BE: Com-parative in vitro activity of PI1127391, a new fluoroqui-nolone agent, against susceptible and resistant clinical Isolates of Gram-positive cocci. Antimicrob. Agents Chemother. (1992) 36:1325–1328.
  • BARRETT MS, JONES RN, ERWIN ME, JOHNSON DM, BRIGGS BM: Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM- 1091) and P0131628. Diagn. Microbial. Infect. Dis. (1991) 14:389–410.
  • ALDRIDGE RE, GELFAND MS, SCHIRO DD, BARG NL: Therapid emergence of fluoroquinolone-methicillin-resis-tant Staphylococcus aureus infections in community hospital. Diagn. Microbial. Infect. Dis. (1992) 15:601–608.
  • THOMSON KS, SANDERS CC, HAYDEN ME: Its vitro studieswith five quinolones: evidence for changes in relative potency as quinolone resistance rises, Antimicrob. Agents Chemother. (1991) 35:2329–2334.
  • KING A, BOOTHMAN C, PHILLIPS I: The in vitro activityof P13127391, a new quinolone. Antimicrob. Agents Chemother. (1988) 32:135–141.
  • BAUERNFEIND A: Comparative in vitro activities of thenew quinolone, Bay y 3118, and ciprofloxacin, spar-floxacin, tosufloxacin, CI-960 and CI- 990.j Antimicrob. Chemother. (1993) 31:505–522.
  • HOLT HA, BOWKER KE, REEVES DS, MACGOWAN AL: Invitro studies with clinafloxacin and nine other antimi-crobials against over 400 anaerobe strains isolated from human in the United Kingdom. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F179.
  • GEISS HK, BAYERL D, SONNTAG H-G: Comparative an-timicrobial activity of clinalloxacin and 8 other broad-spectrum antibiotics against 569 blood culture isolates. 35th Interscience Conf. Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F180.
  • MARTINEZ-BELTRAN J, CANTON R, ALVAREZ M, SIERRAMP, DE RAFEL L, BAQUERO F: Clinafloxachn compara-tive in vitro activity against respiratory tract bacterial pathogens. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F181.
  • GOLDSTEIN EJC, CITRON DM: Comparative activity of ciprofioxacin, ofloxacin, sparfloxadn, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacte-ria. Antimicrob. Agents Chemother. (1992) 36:1158–1162.
  • KAATZ GW, SEO SM, LAMP KC, BAILEY EM, RYBAK MJ: CI-960, a new fluoroquinolone, for therapy of experi-mental ciprofloxacin-sus ceptible and -resistantStapby-lococcus aureus endocarditis. Antimicrob. Agents Chemother. (1992) 36:1192–1197.
  • JOANNIDES EF, ROLAND GE, SESNIE JC, SHAPIRO MA: Comparative in vivo activity of clinafloxacin against methicillin, ciprofloxacin resistant Staphylococcus aureus. 35th Interscience Conf. Antimicrobial Agents Chemother, San Francisco (1995) Abstr:C66.
  • DOOR MB, WEEB CL, BRON N'JASSOS AB: Single-dose tolerance and pharmacokinetics of CI-960 (P1)127391) in healthy volunteers. 31st Interscience Conf Antimicro-bial Agents Chemother., Chicago (1991) Abstr:1154.
  • ELIOPOULOS GM, KLIMM K, ELIOPOULOS CT, FERRARO MJ, MOELLERING RC: In vitro activity of CP-59219, a new fuoroquinolone, against clinical isolates of gram posi-tive bacteria. 32nd Interscience Conf Antimicrobial Agents Chemother., Anaheim (1992) Abstr:236.
  • BRYSKTER A: Update on fluoroquinolones. Carr. opin. invest. drugs (1994) 3:41–49.
  • GOODING BB, JONES RN: In vitro antimicrobial activity of CP-99219, a novel azabicyclo-naphthyridone. Antimi-crob. Agents Chemother. (1993) 37:349–353.
  • KLUGMAN KP, WASAS A: In vitro activity of the fluoro-quinolone CP- 99,219 against penicillin-resistant Strep-tococcus pneumoniae. 34th Interscience Conf. Antimicrobial Agents Chemother., Orlando (1994) Abstr:F16
  • ICNAPP JS, NEAL SW, PAREKH MC, RICE RJ: In vitro activity of new quinolone, CP-99,219 against Neisseria gonor-rhoeae. 34th Interscience Conf Antimicrobial Agents Chemother., Orlando (1994) Abstr:F18 54.
  • SPANGLER SF, JACOBS MR, APPLEBAUM PC: Activity of CP-99,219 compared to that of ciprofloxadn, OPC 17116, metronidaz,ole, cefoxitin, piperacillin and piper-acMinitazobactam against 489 anaerobes. 34th Inter-science Conf Antimicrobial Agents Chemother, Orlando (1994) Abstr:F20 54.
  • ALDRIDGE KE, ASfICRAFT D: Comparison of the in vitroactivity of CP- 99,219 to that of dprofloxacin and other antimicrobials against clinical strain of the Bacteroides fragilis group. 35th Interscience Conf Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F232 153.
  • ZINNER SH, GILBERT DH, DUDLEY MN: CP-99,219: Pre-dictive value of MIC on bacterial activity vs. enterococci. 35th Interscience Conf Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F234 154.
  • BROWN SD, BARRY AL, FUCHS PC: Spontaneously occur-ring Staphylococcal mutants resistant dnically achiev-able concentrations of ciprofloxacin and CP 99,219, a new fluoroquinolone. 35th Interscience Conf Antimicro-bial Agents Chemother., San Francisco (1995) Abstr:F235 154.
  • GIRARD AE, FAIELLA JA, CIMOCHOWSKI CR, BRIGHTY ICE: In vivo activity of CP- 99,219 in models of acute and localized infection in mice. 33rd Interscience ConfAn-timicrobial Agents Chemother., New Orleans (1993) Abstr:1510.
  • GIRARD AE, CIMOCHOWSKI CR, GIRARD D, GOOTZ TD, BRIGHTY ICE: In vitro and in vivo activities of CP-99,219 against Helicobacter. 34th Interscience Conf Antimicrobial Agents Chemother., Orlando (1994) Abstr:F24 55.
  • PARIS MM, HICKEY SM, TRUJILLO M, SHELTON S, McCRACICEN GH: Efficacy of CP- 99,219, a new fluoro-quinolone, for therapy of experimental meningtis caused by penicillin and cephalosporin-resistant Strep-tococcus pneumoniae. 34th Interscience ConfArttimicro-bial Agents Chemother, Orlando (1994) Abstr:F26 55.
  • TENG R, GIRARD D, GOOTZ TD, FOULDS G, LISTON TE: Phannacokinetics of trovafloxacin ( CP-99,219), anew quinolone, in rats, dogs, and monkeys. Antimicrob. Agents Chemother. (1996) 40:561–566.
  • POLZER RJ, POTCHOIBA MJ, RENOUF DN, WEST M, LISTON TE: Distribution of [C14] CP-99,219 into gastric tissue of Long-Evans rats and Swiss- Webster mice following Intravenous administration. 34th Interscience Conf An-timicrobial Agents Chemother, Orlando (1994) Abstr:F30 55.
  • TENG R, HARRIS SC, NIX D, SCHENTAG J, FOULDS G, SILBER BM, LISTON TE: Pharmacokinetics of CP-99,219, a new quinolone antibiotic, following single oral doses to healthy volunteers. 33rd Interscience ConfAntimicro-bial Agents Chemother., New Orleans (1993) Abstr:1512.
  • TENG R, DOGOLO LC, WILLAVIZE SA, VINCENT J: Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volun-teers. 35th Interscience Conf. Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F238 154.
  • VINCENT J, TENG R, DOGOLO LC, WILLAVIZE SA: Effect of steady-state CP- 99,219 on the pahrmacokinetics of single and multiple doses of theophylline in healthy male volunteers. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F239 155.
  • MANN HJ, BIT !ERMAN PB, ANDERSON AC, TENG R, JOHNSON A, AVERY M, VINCENT J: CP-99,219 Penetration Into human bronchial tissues andfluids following the administration of a single dose. 35th Interscience Conf AntimicrobialAgents Chemother, San Francisco (1995) Abstr: F241 155.
  • WISE R, MORHBOY D, CHILD J, ANDREWA JM: Pharma-cokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. (1996) 40:47–49.
  • BRIGHTY ICE, GOOTZ TD,GIRARD A, SHANKER R, CAS-TALDI MJ, GIRARD D, MILLER SA, FAIELLA J: Prodrug of CP-99,219 for intravenous administration: Synthesis and evaluation resulting in identification of CP-116517. 34th Interscience ConfAntimicrobial Agents Chemother, Or-lando (1994) Abstr:F28 55.
  • TENG R, VINCENT J, BARIS B, WILLAVIZE SA: Pharmacok-inetics of single and multiple intravenous doses of CP-116,517, the prodrug pf CP-99,219, in healthy male volunteers. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F24 155.
  • NISHINO T, HOHMURA M, OTSUKI M: In vitro and in vivo activities of DU- 6859a as a parental quinolone. 34th Inrscience Conf Antimicrobial Agents Chemother., Orlando (1994) Abstr:F69 111.
  • MIYAZAKI S, TATEDA K, MATSUMOTO T,TSUIJI M, ASAHI Y, YAMAGUCHI K: In vitro and in vivo comparison of DU-6859a with injectable drugs tested against clinical Isolates. 34th Interscience ConfAntimicrobial Agents Chemother, Orlando (1994) Abstr:F71 111.
  • KIMURA Y, ATARASHI S, KAWAKAMI K, SATO K, HAYAK-AWA I: (Fluorocyclopropyl)quinolone. 2. Synthesis and stereochemical structure-activity relationships of chiral-(7-amino-5-azaspirc42.41heptan-5-y1)-1-(2-fluor ocyclopropyl)quinolone antibacterial agents. J. Med. Chem. (1994) 37(20):3344–3352.
  • MARSHALL SA, JONES RN: In vitro activity of DU-6859a, a new fluorocyclopropyl quinokme. Antimicrob. Agents Chemother. (1993) 37:2747–2753.
  • CHIN NX, HUANG 11B, NEU HC: In vitro activity of DU-6859a, a new fluoroquinolone. 33rd Interscience ConfAntimicrobial Agents Chemother, New Orleans (1993) Abstr:983.
  • THOMSON KS, SANDERS CC: Differences in quinolone resistance among staphylococcal, enterococcal and pnetunococcal mutants. 34th Interscience Conf Antimi-crobial Agents Chemother, Orlando (1994) Abstr:F59 110.
  • KAKU M, YOSHIDA R, KOHNO S, ISHIDA K, MIZUKANE R, TAKEMURA H, YANAKA H, TOMONO K, KOGA H, USUI T: In vitro sntimicrobial activity of DU-6859a against peni-cillin resistant Streptococcus pneumoniae . 34th Inter-science ConfAntimicrobial Agents Chemother, Orlando (1994) Abstr:F61 110.
  • STRAUSS J, BURT J, PHILLIPS AM, CONLY JM: Susceptibility of clinical isolates of Xanthomonas (Xm) meltophilia to newer antimicrobial agents with evidence of increas-ing resistance to beta-lactam. 34th Interscience ConfAn-timicrobial Agents Chemother, Orlando (1994) Abstr:F67 110.
  • VISAUI MA, JACOBS MR, APPELBAUM PC: M1C and time-kill study of cefotaxime, imipenem, and vancomycht against nine penicillin- susceptible and -resistant pneu-mococci Antimicrob. Agents Chemother. (1996) 40:362–366.
  • KATO H, WATANABE K, KATO H, TANAKA K, TANAKA Y, UENO K: Comparative in vitro activity of DU-6859a, a new quinolone, against anaerobic bacteria. 33rd In ter-science ConfAntimicrobial Agents Chemother, New Orleans (1993) Abstr:80.
  • TANAKA M, AOKI H, KURATA T, OKAZAKI 0, HAKUSUI H: DU-6859a, a novel quinolone: pharmacokinetics in rats, dogs, and monkeys. 33rd Interscience ConfAntimicrobial Agents Chemother., New Orleans (1993) Abstr:1000.
  • NAICASHINA M, UEMATSU T, KOSUGE K, UMEMURA K, HAKUSUL H, TANAKA M: Pharmacokinetics and toler-ance of DU6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimi-crob. Agents Chemother. (1995) 39:170–174.
  • USTI Y, TAKASHITA M, MASUDA N, DOMAI H, ISHII C, OHYA S, YASUDA H, IWATA M, KIMURA T, INOLTE T, FUJIHARA Y, KATSUBE T, KUWAHARA S: in vitro evalu-ation of CS-940. 33rd Interscience ConfAntimicrobial Agents Chemother, New Orleans (1993) Abstr:1506.
  • SENDA H, IWATANI W, WATANUKI Y, MAEJIMA T, ARIA T, NAKANO J, FUKUI FL HAIJO H, KYU H: Biological evalu-ation of a novel quinolone derivative with excellent activity against quinolone-resistant S. aureus . 33rd In-terscience Conf Antimicrobial Agents Chemother, New Or-leans (1993) Abstr:1016.
  • JOHNSON DM, JONES RN, ERWIN ME: In vitro antimicro-bial activity of CP- 99,433, a new fluoroquinolone. 33rd Interscience ConfAntimicrobial Agents Chemother., New Or-leans (1993) Abstr:1014.
  • X1COTA MA, GUINEA J, MIRELIS B, PARES M, PRATS G: In vitro activity of new quinolones E-4721, E-4767 and E-5065 on ciprofloxacin-resistant bacterial strains. 33rd Interscience Conf Antimicrobial Agents Chemother., New Or-leans (1993) Abstr:1017.
  • SANCHEZ JP, BRIDGES AJ, BUCSH R, DOMAGALA JM, GoGLuorri RD, HAGEN SE, HEIFETZ CL, JOANNIDES ET, SESNIE JC, SHAPIRO MA, SZOTEK DC: New 8-( fluoromethyp-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risks. f Med. Chem., (1992) 35:361–367.
  • MATSUBARA S, MATSUMOTO M, KONODO A, NAGANO H, YOKOTA T: Photostability of a new 8-methoxy qui-nolone Q-35 following long wave ultraviolet (UVA) radiation. 32nd Interscience Conf.Antimicrobial Agents Chemother, Anaheim (1992) Abstr:1012
  • KITANI H, KURODA T, MORIGUCHI A, HIKIDA K, AO H, YOKOYAMA Y, HIRAYAMA F, IKEDA Y: Novel 7-substi-tutd-fluoroquinolones as potent antibacterial agents: Synthesis and structure-activity relationships. 35th In-terscience Conf Antimicrobial Agents Chemother, San Fran-cisco (1995) Abstr:F190 146.
  • YOKOYAMA Y, MORITVIOTO M, IWAO E, YAMAMOTO K, HONJO K, HIRAYAMA F, IKEDA Y: Y-688, a new fluoro-quinolone with high activity against quinolone resis-tant Gram-positive bacteria. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F191 146.
  • MAEJIMA T, SENDA H, IWATANI W, TATSUMI Y, ARIKA T, FUKUI H, SHIBATA T, NAKANO J, NAITO T: Potent an-tibacterial activity of S-32730, a new fluoroquinolone, against Grain-positive bacteria including quinolone-resistant MESA. 35th Interscience Conf Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F189 146.
  • KIM Y-K, VHOI H, KIM S-H, CHANG J-H, NAM D-H, KIM Y-Z, LEE Y-H, KWAK J-H, HONG C-Y: Synthesis and antibacterial activities of LB20304: A new fluoro-naphthyridone antibiotic containing novel oxime func-tionalized pyrrolidine. 35th Interscience Conf. Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F204 148.
  • OH J-I, AHN M-J, PAEK K-S, KIM M-Y, SE0 M-K, LEE Y-H, HONG CY, NAM D-H, KIM Y-Z, KIM I-C, KWAK J-11:/n vitro and in vivo antibacterial activities of LB20304, a new fluoronaphthyridone. 35th Interscience Conf Antimicro-bial Agents Chemother, San Francisco (1995) Abstr:F205 148.
  • OKEZAKI E, WATANABE Y, HIROSE T, YOSHIDA T, AOKI Y, KATO H: Antibacterial activity of HSR-903, a new novel quinolone. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F202 148.
  • MURATA M, TAKAHARA E, NAGATA 0, KATO H, TAMAI I, TSUJI A: Carrier- mediated tissue distribution and phar-macokinetics of HSR-903, a new quinolone. 35th Inter-science Conf. Antimicrobial Agents Chemother., San Francisco (1995) Abstr:F203 148.
  • LEE KH, KIM JW, CHO IW, LEE JM, YOON YH, LEE KH, SONG SB, HWANG HS: Practical synthesis of C1C-222, a new fluoroquinolone. 35th Interscience Conf Antimicro-bial Agents Chem other., San Francisco (1995) Abstr:F198 147.
  • KIM JH, KANG JA, HONG KH, LEE ICH, SONG SB, HWANG HS, PARK KH: In vitro antibacterial activity of CFC-222 against penicillin-susceptible and -resistant Streptococ-cus pneumoniae. 35th Interscience Conf Antimicrobial Agents Chemother, San Francisco (1995) Abstr:F199 147.
  • KIM JH, KANG JA, KIM YG, HONG KH, LEE KH, CHO IH, LEE JM, PARK KH: In vitro antibacterial activity of CFC-222, a new quinolone. 35th Interscience Conf Antimicro-bial Agents Chemother, San Francisco (1995) Abstr:F200 148.
  • CECCHETTI V, CLEMENT' S, CRUCIANI G, FRAVOLINI A, PAGELLA PG, SAVINO A, TABARRINI 0: 6-Aminoqui-nolones: Anew class of quinolone antibacteriaLs?/ Med. Chem. (1995) 38:978–982.
  • WAITES KB, DUFFY LB, SCHMID T, CRABB D, PATE MS, CASSELL GH: In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma bominis, and Ureaplasma ureaOticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. (1991) 35:1181–1185.
  • KENNY GE, CARTWRIGHT FD: SusceptibRitis of Myco-plasma pneumoniae, Mycoplasma bominis and Urv-aplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. (1996) 40:1048–1049.
  • CASSELL GH, CLYDE WA, DAVIS JK: Mycoplasmal respi-ratory infections. In RAZIN S, BARILE MF (Ed) The myco-plasma, Academic Press, Inc., New York (1988) 65–106.
  • ARAI S, GOHARA Y, AKASHI A, KUWANO K, NISHMOTO M, YANO T, OIZUMI K, TAICEDA K, YAMAGUCHI T: Effects of new quinolones on Mycoplasma pneumoniae- in-fected hamsters. Antimicrob. Agents Chemother. (1993) 37:287–292.
  • ITO T, OTSUKI M, NISHINO T: In vitro antibacterial activity of Q-35, a new fhioroquinolone. Antimicrob. Agents Chemother. (1992) 36:1708–1714.
  • GOHARA Y, ARAI S, AKASHI A, KUWANO K, TSENG C-C, MATSUBARA S, MATUMOTO M, EURUDERA T: In vitro and in vivo of Q-35, a new fluoroquinolone, against Myco-plasma pneumoniae. Antimicrob. Agents Chemother. (1993) 37:1626–1830.
  • GRAYSTON JT, CAMPBELL LA, KUO C-C, MORDHORST CH, SAIKKU P, THOM DH, WANG SP: A new respiratory tract pathogen: Cblamydia pneumoniae strain TWAR. J. In-fect. Dis. (1990) 161:618–625.
  • HAMMERSCHLAG M, QUMEI KK, ROBIN PM: In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Cblamydia pneumoniae. Antimicrob. Agents Chemother. (1992) 36:1573–1574.
  • EDELSTEIN PH, EDELSTEIN MAC, WEIDENFELD J, DORR MB: In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with I- pneu-mopbila pneumonia. Antimicrob. Agents Chem other. (1990) 34:2122–2127.
  • EDELSTEIN PH, EDELSTEIN MAC, HOLZKNECHT: In vitro activities of fieroxacin against clinical isolates of Le-gionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumopbila pneumo-nia. Antimicrob. Agents Chemother. (1992) 36:2387–2391.
  • EDELSTEIN PH, EDELSTEIN MAC, REN J, POLZER R, GLADUE R: Activity of trovafloxacin (CP-99,219) against Legionella Isolates: In vitro activity, intracelhilar accu-mulation and killing in macrophages, and pharmacok-inetics and treatment of guinea pigs with L pneumopbia pneumonia. Antimicrob. Agents Chemother. (1996) 40:314–319.
  • SAITO A, KUSANO N, HIGA H, MIYARA T: In vitro and in vivo antibacterial activities of DU-6859a and its intracel-lular activity against Legionella pneumophia. 33rd In-terscience ConfAntimicrobial Agents Chemother., New Orleans (1993) Abstr:991.
  • GATES W JR, WASSERHEIT JN: Gential chiamydial infec-tions: epidemiology and reproductive sequelae. Am. J. Obstet. Gynecol. (1991) 164:1771–1781.
  • NAGAYAMA A: In vitro activities of DU-6895a and other quinolones against Cbamydia tracbomatis. 33rd Inter-science ConfAntimicrobial Agents Cbemotber.,New Orleans (1993) Abstr:994.
  • PATTON DL, COSGROVE YT, KUO C-C, CAMPBELL LA: Effects of quinolone analog CI-960 in a monkey model of Cblainydia tracbomatis Salpingitis. Antimicrob. Agents Chemother. (1993) 37:8–13.
  • GARCIA-RODRIGUEZ JA, GRACIA SANCHEZ JE, TRUJIL-LANO I, MUNOZ BELLIDO JL: In vitro activity of new quinolones against Brucella species. Rev. Infect. Dis. (1989) 11 (Suppl. 5):S992–S993.
  • GOBERNADO M, CANTON E, SANTO M: In vitro activity of ciprofloxacin againstB. melitensis. Eur.J. Clin. Micro-biol. (1984) 3:371
  • KLAN MY, DIZON M, KIEL FW: Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antibiotics against Brucella melitensis. Antimicrob. Agents Chemother. (1989) 33:1409–1410.
  • RLTBINSTEIN E, LANG R, SHASHA B, HAGAR B, DIAMAN-STEIN L, JOSEPH G, ANDERSON M, HARRISON K: In vitro susceptibility of Bruce/a melitensis to antibiotics. An-timicrob. Agents Chemother. (1991) 35:1925–1927.
  • AL-SIBAI MB, HALIM MA, EL-SHAKER MM, KHAN BA, QADRI MH: Efficacy of ciprofloxacin for the treatment of Brucella melitensis infections. Antimicrob. Agents Chemother. (1992) 36:150–152.
  • LANG R, RAZ R, SACK T, SHAPIRO M: Failure of prolonged treatment with ciprofloxacin in acute brucellosis. J. Antimicrob. Chemother. (1990) 26:841–846.
  • AKALIN HE, UNAL S, GUR D, BAYKAL M: Ofloxacin in the treatment of brucellosis. Eur.J. Clin. Microbiol. Infect. Dis. (1990) 326–328.
  • BAYKAL M, AKALINHE, FIRAT M, SERIN Ann vitro activity and clinical efficacy of Ofloxacin in infections due to Brucella melitensis. Rev. Infect. Dis. (1989) 11 (suppl. 5): S993–S994)
  • AKOVA M, UZUN 0, AKALIN HE, HAYRAN M, UNAL S, GUR D: Quinolone in treatment of human brucellosis: com-parative trial of ofloxacin-rffampin vet-us doxycycline-rifampin. Antimicrob. Agents Chemother. (1993) 37:1831–1834.
  • HOPPE JE, SIMON CG: In vitro susceptibilities of Borde-tette pertussis and Bordetella parapertussis to seven fluoroquinolones. Antimicrob. Agents Chemother. (1990) 34:2287–2288.
  • HULL IIF, MONTES JM, MANN JM: Septicemic plague in New Mexico. J. Infect. Dis. (1987) 155:113–118.
  • BONACORSI SP, SCAVIZZI MR, GUIYOULE A, AMOUROLTX JH, CARMEL E: Assessment of a fluoroquinolone, three §-lactams, two aminoglycosides, and a cycline in the treatment of murine Yersins pestis infection. Antimi-crob. Agents Chemother. (1994) 38:481–486.
  • UNE T, OSAD A: Penetrability of ofloxacin into cultured epithelial cells and macrophages. Drug Res. (1988) 38(11):1265–1267.
  • SCHAAD UB: Role of the new quinolones in pediatric practice. Pediatr. Infect. Dis. J., (1992) 11:1043–1046.
  • CHYSKY V, KAPILA K, HULLMANN R, ARCIERI G, SCHACHT P, ECHOLS R: Safety of ciprofloxacin in children: world-wide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection, (1991) 19:289–296
  • STAHLMANN, R, FORSTER, VAN SICKLE C, VAN SICKLE D: Quinolones in children: are concerns over arthropathy justified? Drug safety., (1993) 9:397–403.
  • WOULD HEALTH ORGANIZATION STUDY GROUP: Che-motherapy of leprosy for control programmes. WHO Tech. Rep. Ser. 675 (1982)
  • WORLD HEALTH ORGANIZATION: Leprosy situations in the world and multidrug therapy coverage. Weekly Epidemiol. Re. (1992) 67:153–160.
  • JIB, GROSSET JH: Recent advances in the chemotherapy of leprosy. Lepr. Rev, (1990) 61:313-329 ( Editorial).
  • GROSSET JH, GUELPA-LAURAS CC, PERANI EG, BEOLETTO C: Activity of ofloxacin against Mycobacterium leprae in mouse. Int. J. Lepr. (1988) 56:259–264.
  • GROSSET jH, JI B, GUELPA-LAURAS CC, PERANI EG, N'DELI LN: Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. (1990) 58:281–295.
  • JI B, PERANI EG, PETIMON C, N'DELI L, GROSSET JH: Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepro-matous leprosy. Antimicrob. Agents Chemother. (1994) 38:662–667.
  • JI B, JAMET P, PERANI EG, BOBIN P, GROSSET JH: Powerful bacterial activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy J. Infect. Dis. (1993) 168:188–190.
  • BLOCH AB, REIDER HL, KELLY GD, CAUTHEN GM, HAY-DEN CH, SNIDER, Jr DE: The epidemiology of tuberculo-sis in the United States: implications for diagnosis and treatment. Clin. Chest. Med. (1989) 10:297-313 ( Erratum 11:1, 1990).
  • JEREB JA, KELLY GD, DOOLEY, JR SW, CAUTHEN GM, SNIDER, JR DE: Tuberculosis morbidity in the United States: final data. Morbid. Mortal. Weeky Rep. CDC Surveil!. Summ. (1990) 40:23–27.
  • BARNES PF, BLOCH AB, DAVISON PT, SNIDER, JR DE: Tuberculosis in patients with human immuodeflciency virus infection. N. Engl. J. med. (1991) 324:1644–1650.
  • CENTER FOR DISEASE CONTROL: Nosocornial transmis-sion of multi-drug resistant tuberculosis among HIV infected persons - Florida and New York, 1988-1991. Morbid. mortal. Weekly Rep. (1991) 40:585–591.
  • GORZYNSKI EA, GUTMAN SI, ALLEN W: Comparative antimycobacterial activities of difloxacin, ternaflox-acin, enoxacin, pefloxacin, reference fluoroqui-nolones, and a new macrolide, clarithrotnycin. Antimicrob. Agents Chemother. (1989) 33:591–592.
  • JI B, TRUFFOT-OERNOT C, GROSSET J: In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobac-terium tuberculosis Tubercle (1991) 72:81–186.
  • LEYSEN DC, HAEMERS A, PATTYN SR: Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. (1989) 33:1–5.
  • RASTOGI N, GOH KS: In vitro activity of the new difluor-inated quinolone sparfloxacin (AT-4140) against Myco-bacterium tuberculosis compared with activities of ofloxacin, ciprofloxacin. Antimicrob. Agents Chemother. (1991) 35:1933–1935.
  • FRIEDEN TR, STERLING T, PABLOS-MENDEZ A, KILBURN JO, CAUTHEN GM, DOOLEY SW: The emergence of drug-resistant tuberculosis in New York City. N. ENGL. J. MED. (1993) 328:521–526.
  • SAITO H, TOMIOKA H, SATO K, DEKIO S: In vitro and in vivo anti- mycobacterial activities of a new quirtolone, DU-6859a. Antimicrob. Agents Chemother. (1994) 38:2877–2882.
  • TOMIOKAH, SAITO H, SATO K: Comparative antimyco-bacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob. Agents Chemother. (1993) 37:1259–1263.
  • HEIFETS LB, LINDHOLM-LEVY Pj: MICs and MilCs of WIN 57273 against Mycobacterium avium and M. tuberculo-sis. Antimicrob. Agents Chemother. (1990) 34:770–774.
  • RASTOGI N, BLOM-POTAR MC: Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Myco-bacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line. Int. Med. Microbiol. (1990) 273:195–199.
  • SKINNER PS, FURNEY SK, KLEINERT DA, ORME IM: Com-parison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculo-sis. Antimicrob. Agents Chemother. (1995) 39:750–753.
  • HONG KONG CHEST SERVICE, BRITISH MEDICAL RE-SEARCH COUNCIL: A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampin. Tuberc. Lung Dis. (1992) 73:59–67.
  • KOHNO S, KOGA H, KATU M, MAESAKI S, HARA: Prospec-tive comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest ( 1992) 102:181 5–1818.
  • TSUKAMURA M, NAKAMURA E, YOSHII S, AMANO H: Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. ( 1985) 131:352–356.
  • NAKAE I, NAKATANI K, INOSUE S: Therapeutic effect of ofloxacin in intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients. Kekkaku (1991) 66:299–307
  • RASTOGI N, ROSS BC, DWYER B, GOH KS, CLAVEL-SERES S, JEANTILS V, CRUAVA P: Emergence during unsuccess-ful chemotherapy of multiple drug resistance in strain of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 10:901–907.
  • MEISSNER G, ANZ W: Source of Mycobacterium avium-complex infection resulting from human disease. Am. Rev. Respir. Ms:. (1977) 116:1057–1065.
  • TSUKAMURA M: In vitro antimycobacterial activity of a new substance DL-8280- differentiation between some species of mycobacteria and related organisms by the DL-8280 susceptibility test. Microbiology and Immunology (1983) 27:1129–1132.
  • VAN CAEKENBERGHE DV: Comparative in vitro activities of ten fluoroquinolones and fusidic add gainst Myco-bacterium spp. J. Antimicrob. Cbemotber. (1990) 26:381–386.
  • KLOPMAN G, WANG S, JACOBS MR, NAJAKSOUZIAN S, EDMOND K, ELLNER JJ: Anti- Mycobacterium avium activity of quinolones: in vitro activities. Antimicrob. Agents Chemotber. (1993) 37:1799–1806.
  • KLOPMAN G, WANG S, JACOBS MR, ELLNER JJ: Anti-My-cobacterium avium activity of quinolones: structure-ac-tivity relationship studies. Antimicrob. Agents Chem other. (1993) 37:1807–1815.
  • BERMUDEZ LE, INDERLIED CB, KOLONOSKI P, WU M, BARBARA-BURNHAM L, YOUNG LS: Activities of Bay Y 3118, Levofioxacin, and ofloxacin alone or in combina-tion with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob. Agents Chemotber. (1996) 40:546–551
  • ONYEJI CO, NIGHTINGALE CH, NICOLAU DP, QLTIN-TILIANI R: Efficacies of liposome- encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macro-phages. Antimicrob. Agents Chemotber. (1994) 38: 523–527.
  • PATIL MA, KATOCH VM, VENKATESAN K: Correlation between inhibitory effect of quinolones and mycolic metabolism in mycobacteria. Indian J. Lepr. (1992) 64:331–340.
  • WALLACE RJ, JR., SWENSON JM, SILCOX VA: The rapidly growing mycobacteria: characterization and suscepti-bility testing. Antimicrob. Newsl. (1985) 12:85–92.
  • KHARDOR1 N, NGUYEN H, ROSENBAUM B, ROLSTON K, BODEY GP: In vitro susceptibilities of rapidly growing mycobacteria to new antimacrobial agents. Antimicrob. Agents Chemotber. (1994) 38:134–137.
  • WANG JC: DNA topoisomerases . An flu. Rev. Biocbem. (1985) 54:665–697.
  • LIU LF: DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Btochem. (1989) 58:351–375.
  • DRLICA K, FRANCO RJ: Inhibitors of DNA topoisom-erases. Biocbem. (1988) 27:2253–2259.
  • HUSSY P, MAASS G, TUMMLER B, GROSSE F, SCHOMBURG U: Effect of 4- quinolones and novobiodn on calf thymus DNA polymerase alfa primase complex topoi-somerase I and II and growth of mammalian lym-phoblasts. Antimicrob. Agents Chemother. (1 9 8 6) 29:1073-1078.
  • BARRETT JF, GOOTZ TO, McGUIRK PR, FARRELL CA, SOKOLOWSKI SA: Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob. Agents Chemotber. (1989) 33:1697–1703.
  • ROBINSON MJ, MARTIN BA, GOOTZ TO, McGUIRK PR, OSHEROFF N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase influ-ence of C-8 fluorine group. Antimicrob. Agents Chemother. (1992) 36:751–756.
  • ROBINSON MJ: Effects of quinolone derivatives on eu-karyotic topoisomerase II: a novel mechanism for en-hancement of enzyme- mediated DNA cleavage. J. Biol. Chem. (1991) 266:4585–14592.
  • CORBETT AH, GUERRY P, PFLIEGER P, OSHEROFF N: A pyrimido[1,6-a] benzirnidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Antimicrob. Agents Chem other. (1993) 37:2599–2605.
  • HOSHINO K, SATO K, AKAHANE K, YOSHIDA A, HAYAK-AWA I, SATO M, UNE T, OSADA Y: Significance of methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob. Agents Chemother. (1991) 35:309–312.
  • KOHLBRENNER WE, WIDEBURG N, WEIGL D, SALDIVAR A, CHU DTW: Introduction of calf thymus topoisom-erase II-mediated DNA breakage by antibacterial isothi-asoloquinolones, A-65281 and A-65282. Antimicrob. Agents Cbernother. (1992) 36:81–86.
  • CHU DTW: Isothiazoknyinolones: antibacterial and an-tineoplastic agents. Drug Future (1992) 17:1101–1109.
  • CHU DTW, HALLAS R, CLEMENT JJ, ALDER J, McDONALD E, PLATTNER JJ: Synthesis and antitumour activities of quinolone antineoplastic agents. Drugs Exptl. Clin. Res. (1992) 18:275–282.
  • CLEMENTE, BURNES N, JARVIS K, CHU DTW, SWINIARSKI J, ALDER J: Biological characterization of a novel antitu-mor quinolone. Cancer Res. (1995) 55:830–835
  • PERMANA PA, SNAPKA RM, SHEN LL, CHU DTW, CLEMENT JJ, PLATTNER JJ: Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic Inhibitors. Biochemist(1994) 33:11333–11339.
  • GOLLAPLTDI S, THADEPALLI F, KIM CH, GUPTA S: Diflox-acin reverses multidrug resistance in HL-60/AR cells that overes press the mukidrug rsistance- related pro-tein (MRP) gene. Oncol. Res. (1995) 7 (5):213–225
  • GUPTA S, THADEPALLI F, GOLLAPUDI S: Difloxacin re-verses multidrug resistance in P388/ADR cells via a mechanism independent of P- glycoprotein and with-out correcting drug transport or subeellular drug dis-tribution. Int. J. Oncol. (1995) 7(3):475–80.
  • BAUER WR, RESSNER EC, KATES J, PATZKE JV: A DNA nicking-closing enzyme encapsidated in vaccinia virus: Partial purification and properties. Proc. Natl. Acad. Sci. U.S.A. (1977) 74:1841–1845.
  • KREUZER KN: DNA topoisomerases as potential targets of antiviral action. Pharmac. Ther. (1989) 43:377–395.
  • PORTOLANI M, PIETROSEMOLI P, CERMELLI C, MANNINI PALENZONA A, GROSSI MP, PAOLINI L, BARBANTI-BRO-DANO G: Suppression of BK virus replication and cytho-pathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res. (1988) 9:205–218.
  • RAINWATER R, MANN K: Association of topoisomerase I and 11 with the chromatin in SV40-infected monkey cells. Virology(1991) 181:408–411.
  • IKEDA S, YAZAWA M, NISHIMURA C: Antiviral activity and inhibition of topoisomerase by ofloxacin, a qui-nolone derivative. Antiviral Res. (1987) 8:103–113.
  • WENTLAND MP, PERNI RB, DORFF PH, BRUNDAGE P, CASTALDI MJ, BAILEY TR, CARABATEAS PM, BACON ER, YOUNG DC, WOODS MG, ROSI D, DROZD ML, KULLNIG ER, DUTKO FF: 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. J. Med. Chem. (1993) 36:1580–1596.
  • FAN T, FU X, ZHANG G, ZHANG N: The inhibitory effects of quinolones on hepatitis B virus in vitro. Virologica Sinica (1994) 9(2):113–118
  • NAKAJIMA R, KITAMURA A, SOMEYA K, TANAKA M, SATO K: In vitro and in vivo antifungal activity of Du-6859a, a fluoroquinolone, in combination with amphotericin Band fluconazole against pathogenic fungi. Antimicrob. Agents Cbemother. (1995) 39:1517–1521.
  • SARMA PS: Norfloxacin: a new drug in the treatment of Falciparum malaria. Ann. of Int. Med. (1989) 111:336–337.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.